The Society for Neuroscience (SfN) is pleased to recognize Abcam as the Sponsor of the Day for the second day of Neuroscience 2022, Sunday, November 13, 2022.

The Society for Neuroscience (SfN) is pleased to recognize Elsevier as the Sponsor of the Day for the opening day of Neuroscience 2022, Saturday, November 12, 2022.

The Society for Neuroscience (SfN) is pleased to announce the Platinum and Gold sponsors of SfN’s 51^st annual meeting, Neuroscience 2022. Abcam and Elsevier are serving as the meeting’s two Platinum sponsors, the highest level of sponsorship available.

SfN enthusiastically announces that Neuroscience 2021 will be held in an inclusive hybrid format. Neuroscience 2021 is one annual meeting with two experiences: for the first time, a four-day full virtual program (November 8-11, 2021) including reimagined virtual posters, and a four-day full in-person program in Chicago at McCormick Place Convention Center (November 13–16, 2021).

SfN President Diane Lipscombe, PhD, President-Elect Barry Everitt, PhD, and Past President Richard Huganir, PhD, released the following statement, reflecting on those who were unable to attend Neuroscience 2018 because of restrictive travel policies in the United States and other countries and continuing to affirm the Society’s support for free exchange of information, diversity, and global collaboration in science.

New research revealed today highlights the power of animal studies to explore mechanisms of opioid addiction, withdrawal, and relapse to inform new prevention strategies and treatments for people. 

Sleep disruptions are associated with many brain disorders, including anxiety, dementias, and traumatic brain injury. While these disruptions are sometimes viewed as a side effect of brain disorders, new findings presented today suggest that aberrant sleep-wake cycles can also drive brain pathology.

Studies that link breakdowns in the brain’s blood vessels to Alzheimer’s disease and vascular dementia were presented today at Neuroscience 2018, the annual meeting of the Society for Neuroscience and the world’s largest source of emerging news about brain science and health.

Promising findings from preclinical animal studies show the potential of gene therapy for treating incurable neurological disorders. In new research presented today, scientists successfully used gene therapy to slow the progression and improve symptoms of disorders such as amyotrophic lateral sclerosis and Parkinson’s disease.

While solitary confinement is an extreme example affecting a relatively small portion of the population, social isolation and persistent loneliness are a growing problem in the United States.